secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0000950170-22-020257
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics COO Lawrence Klein resigns; search for successor underway
-----------------------------------------------------------------------------

- COO Lawrence Klein, Ph.D., resigns effective Oct 27, 2022; will stay through year-end for transition.
- CEO Samarth Kulkarni thanked Klein for seven years of contributions to strategy and leadership.
- Company is conducting a search to find a successor for the COO role.
- Klein cited exa-cel poised for regulatory filing and five other clinical programs as company strengths.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022020257/0000950170-22-020257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022020257/crsp-20221027.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer